Emerging landscape in psoriasis management: From topical application to targeting biomolecules

•Recent advancements in targeting therapy have made a revolution in the treatment of psoriasis.•Topical nanocarriers are the potential delivery systems for multiple drugs with prolonged action, reduced dosage administration and better patient compliance.•Biologics agents target the T cells or block the proteins like tumor necrosis factor, interferon-γ and interleukins.•Targeting ability of phosphodiesterase-4 inhibitors, miRNAs and Janus kinases inhibitors at the molecular level proved as an effective therapy for psoriasis. Psoriasis is a chronic autoimmune skin disorder affecting 2–3% of the world population. It has characteristic features such as increased keratinocyte proliferation and production of inflammatory mediators. The treatment involves various strategies including topical, systemic, phototherapy and biologics. Topical therapies are preferred for mild to moderate psoriasis conditions over the systemic therapies which are ideal in severe disease conditions. The systemic therapies include immunosuppressants, biological agents and recently approved phosphodiesterase-4 (PDE4) inhibitors. There are various limitations associated with the existing therapies where the new findings in the pathogenesis of psoriasis are paving a path for newer therapeutics to target at the molecular level. Various small molecules, PDE-4 inhibitors, biologics, and immunomodulator proved efficacious including the new molecules targeting Janus kinases (JAK) inhibitors that are under investigation. Furthermore, the role of genetic and miRNAs in psoriasis is still not completely explored and may further help in improving the treatment efficacy. This review provides an insight into various emerging therapies along with currently approved treatments for psoriasis.